Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ZS-9

AstraZeneca AZ

AZ’s COVID-19 vaccine shows promise in younger and older adults

Company said vaccine produces similar immune response in younger and older adults

- PMLiVE

Both AZ and J&J set to resume US COVID-19 vaccine trials

Both companies paused their trials after separate participant illness events

- PMLiVE

Vaccine developers call on FDA to offer clarity on COVID-19 trials

Comments from J&J and Pfizer made before FDA advisory committee meeting yesterday

- PMLiVE

AZ’s COVID-19 vaccine trial to continue after Brazilian volunteer death

Reports indicate that the death occurred in the placebo group

- PMLiVE

Independent consultant will review Lilly’s COVID-19 plant issues

COVID-19 antibody trial was paused last week due to safety issue

AstraZeneca AZ

AZ’s US-based COVID-19 vaccine trial could restart this week

Sources briefed on the matter disclosed possible timeline to Reuters

- PMLiVE

Regeneron scores first FDA approval for Ebola antibody treatment

Treatment cut mortality rate in study based in the Democratic Republic of Congo

- PMLiVE

Regeneron seeks US emergency use authorisation for COVID-19 antibody cocktail

If approved, the US government will make initial doses available at no cost

- PMLiVE

FDA publishes new guidelines for COVID-19 vaccine approval

New rules mean a COVID-19 shot is unlikely to be approved pre-election in the US

- PMLiVE

Lilly seeks US emergency approval after posting new data for COVID-19 antibodies

Combination of two antibodies reduced viral load and symptoms of COVID-19

- PMLiVE

Moderna CEO says COVID-19 vaccine will be ready for FDA submission in late November

Company will seek emergency use authorisation for experimental vaccine

- PMLiVE

EMA begins rolling review of AZ’s COVID-19 vaccine candidate

Agency has started evaluating data from non-clinical laboratory studies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links